Candin作为新型佐剂的疫苗防治宫颈癌的机制及效果研究

项目名称： Candin作为新型佐剂的疫苗防治宫颈癌的机制及效果研究

项目编号： No.81472439

项目类型： 面上项目

立项/批准年度： 2015

项目学科： 医药、卫生

项目作者： 王雪莲

作者单位： 中国医科大学

项目金额： 72万元

中文摘要： 在宫颈癌的免疫治疗中，诱导强有力的细胞免疫应答是清除病毒感染细胞及肿瘤细胞的关键。目前上市应用的人用疫苗佐剂均不能诱导产生细胞免疫应答。迫切需要开发包含新型人用佐剂的疫苗。我们前期实验发现：Candin（白假丝酵母菌提取物，已被批准在临床使用）可活化朗格汉斯细胞（LC）的模式识别受体，促进LC成熟，增加细胞因子IL-12分泌，增强LC刺激T细胞增殖的作用，具有增强细胞免疫应答的潜能。基于以上结果，我们提出以Candin为佐剂，以HPV蛋白多肽为抗原，开发一种全新的宫颈癌疫苗。通过体外细胞水平及体内动物模型水平深入研究Candin作为疫苗佐剂增强细胞免疫应答的机制及对宫颈癌治疗疫苗效果的影响。研究结果将提供增强细胞免疫的人用疫苗的重要候选佐剂，为开发全新包括宫颈癌在内的肿瘤治疗疫苗研究奠定坚实基础。

中文关键词： Candin；佐剂；疫苗；宫颈癌

英文摘要： It is crucial to induce potent cellular immune response to clear virus infected cells and cancer cells in immunotherapy for cervical cancer. The existing licensed adjuvants can not induce cellular immune response. It is urgent to develop a vaccine including novel adjuvants capable of inducing cellular immune response. The results of early experiments by our group showed Candin (a colorless extract of Candida albicans, a skin test reagent approved by FDA) up-regulated the expression of pattern recognition receptors in Langerhans cells (LC), increased the expression of IL-12 in LC, cause maturation effects on LC and increased T-cell proliferative capacity induced by LC. According to the above results, we plan to develop a novel therapeutic vaccine including Candin as adjuvant and HPV E7 poly-peptide as antigen. The goal of this project is to further investigate the mechanism of Candin as adjuvant to boosting cellular immune response and its effect on the therapeutic vaccine for cervical cancer. The research finding will provide an important candidate adjuvant for boosting cellular immune response. Also, it will lay good foundation for the development of tumor therapeutic vaccine capable of boosting cellular immune response, especially for cervical cancer.

英文关键词： Candin;adjuvant;vaccine;cervical cancer